Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The new heparins].

M Samama1, A Babinet-Berthier

  • 1Laboratoire central d'Hématologie, Hôtel-Dieu, Paris.

Journal Des Maladies Vasculaires
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Low molecular weight heparins (LMWH) offer venous and arterial antithrombotic effects with a lower bleeding risk than standard heparin. Further research is needed to define their efficacy in specific thrombotic conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intra-sinusal bone ring concomitant with Le Fort 1 osteotomy: description of a technique.

Journal of stomatology, oral and maxillofacial surgery·2020
Same author

Mandibular lymphoma.

Journal of stomatology, oral and maxillofacial surgery·2017
Same author

[Applications of simultaneous thrombodynamography (thromboelastography) of plasma rich in platelets (P.R.P.) and of plasma without platelets (P.D.P.) to the problem of thromboses and of their treatment with anticoagulants].

Pathologie et biologie·2014
Same author

Prevention and treatment of venous thromboembolism--International Consensus Statement.

International angiology : a journal of the International Union of Angiology·2014
Same author

Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.

Journal of thrombosis and haemostasis : JTH·2012
Same author

New antiplatelet agents.

Acta anaesthesiologica Belgica·2011
Same journal

Renal function and venous thromboembolic diseases.

Journal des maladies vasculaires·2016
Same journal

[Ankle-brachial index screening for peripheral artery disease in high cardiovascular risk patients. Prospective observational study of 370 asymptomatic patients at high cardiovascular risk].

Journal des maladies vasculaires·2016
Same journal

[Erratum to "When to worry about before a vascular chronic leg ulcer?" [J. Mal. Vasc. 41 (2016) 307-314]].

Journal des maladies vasculaires·2016
Same journal

[Deep venous thrombosis of the upper limb in a violin player: The "bow syndrome"].

Journal des maladies vasculaires·2016
Same journal

[Economic consequences of biological monitoring and medical complications of injectable anticoagulants in France].

Journal des maladies vasculaires·2016
Same journal

[Vitamin K antagonist, direct oral anticoagulants: Where is the truth?]

Journal des maladies vasculaires·2016
See all related articles

Area of Science:

  • Pharmacology and Thrombosis
  • Coagulation Cascade Modulation

Context:

  • Increasing prescription of low molecular weight heparins (LMWH) in France.
  • Standard heparin depolymerization yields LMWH with altered anti-IIa and anti-Xa activity.
  • Uncertainty regarding the precise mechanism of LMWH's in vivo antithrombotic effects.

Purpose:

  • To elucidate the antithrombotic mechanisms and pharmacological profile of LMWH.
  • To compare the efficacy and safety of LMWH with unfractionated heparin.
  • To review current clinical indications and identify areas for further research.

Summary:

  • LMWH exhibits reduced anti-IIa activity and a higher anti-Xa/anti-IIa ratio, suggesting a distinct mechanism of action involving early thrombin inhibition and coagulation amplification.
  • Pharmacological studies demonstrate both venous and arterial antithrombotic activity in animal models, with a comparatively lower bleeding risk than unfractionated heparin.

Related Experiment Videos

  • LMWH shows weak platelet interaction, potentially enhancing efficacy in arterial thrombosis. Renal elimination and high bioavailability (~90%) post-subcutaneous injection are noted. Rare thrombocytopenia cases reported.

    • Impact:

    • Established indications for LMWH in surgical prophylaxis, medical patients, and deep vein thrombosis treatment.
    • Highlights the need for further clinical studies on LMWH efficacy in pulmonary embolism, disseminated intravascular coagulation, myocardial infarction, and post-vascular surgery thrombotic complications.
    • Provides a foundation for understanding LMWH's role in anticoagulation therapy and guiding future clinical practice and research.